Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281567
Status:
COMPLETED
Last Update Posted:
2013-11-01
First Post:
2006-01-24
Brief Title:
Efficacy and Safety Comparison of Tiotropium Inhalation Solution Respimat Inhaler and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease COPD
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomised Double-blind Double-dummy Placebo-controlled Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses 5 μg 2 Actuations of 25 μg and 10 μg 2 Actuations of 5 μg of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler Tiotropium Inhalation Powder Capsule 18μg Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease COPD
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None